Aethlon Medical Q3 operating expenses up 13.6% yr/yr

Aethlon Medical

12/02/2026 21:27

Overview

Medical therapeutic firm's fiscal Q3 operating expenses rose 13.6% yr/yr

Operating expenses for nine months declined 26.9% yr/yr

Company advances Australian oncology trial and Long COVID research

Outlook

Company continues research on Hemopurifier for broader clinical applications

Aethlon advances Long COVID research with Hemopurifier targeting EVs

Company remains committed to advancing clinical programs with operational discipline

Result Drivers

QUARTERLY EXPENSES - Rose 13.6% yr/yr, primarily driven by higher payroll and related costs

COST EFFICIENCY - Year-to-date operating expenses declined 26.9% due to disciplined cost controls

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Operating Expenses
$2.06 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Aethlon Medical Inc is $12.38, about 492.1% above its February 11 closing price of $2.09

Press Release: ID:nPn1qKRy8a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)